Thymus cancer
MONDO:0002586A primary or metastatic malignant neoplasm involving the thymus. This category includes malignant thymomas, thymic lymphomas, primary thymic carcinomas, and metastatic carcinomas from other anatomic sites.
Also known as: thymic neoplasm, thymic tumor, thymic tumour, Thymus cancer, cancer of Thymus, cancer of the Thymus, cancer of thymus, malignant Thymus neoplasm
3047 clinical trials for this condition and its sub-types, 10 tagged with Thymus cancer itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Thymus cancer
-
Thymus lymphoma 0 trials · 175 incl. sub-types
1 sub-type
- Primary mediastinal large B-cell lymphoma 175 trials
-
Thymic carcinoma 41 trials · 44 incl. sub-types
9 sub-types
- Invasive malignant thymoma 4 trials
- Thymic neuroendocrine carcinoma 3 trials Sub-types →
- Lymphoepithelioma-like thymic carcinoma 0 trials
- Malignant type AB thymoma 0 trials
- Thymic sarcomatoid carcinoma 0 trials
- Thymic undifferentiated carcinoma 0 trials
- Thymus clear cell carcinoma 0 trials
- Thymus gland adenocarcinoma 0 trials Sub-types →
- Thymus squamous cell carcinoma 0 trials Sub-types →
Most studied deeper sub-types
-
New hope for rare thymus cancers: PT-112 trial launches
Disease control Recruiting nowThis study tests a drug called PT-112 in people with thymoma or thymic cancer that has come back or worsened after standard treatment. PT-112 is designed to kill cancer cells and boost the immune system. About 53 adults will receive the drug intravenously in 28-day cycles. The ma…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called TNhYP218 CAR T cells for people with solid tumors that have high levels of a protein called mesothelin, including mesothelioma. Participants' own immune cells are collected, modified in a lab to better attack cancer, and then gi…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Keytruda takes on rare chest cancers: early trial launches
Disease control Recruiting nowThis early-phase trial is testing the safety of the immunotherapy drug pembrolizumab (Keytruda) in 37 people with thymoma or thymic carcinoma that cannot be removed by surgery. The drug helps the immune system attack cancer cells. Researchers are looking at side effects and how w…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New radiation approach aims to control thymic cancer spread with fewer side effects
Disease control Recruiting nowThis study is testing a precise type of radiation called IMPRINT for people whose thymic cancer has spread to the lining of the lung (pleura). The main goal is to see if this treatment is safe and causes only mild side effects, especially lung inflammation. About 36 participants …
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
12,000 patients needed to bridge gap between clinical trials and Real-World cancer care
Knowledge-focused Recruiting nowThis study aims to collect health information from 12,000 adults with lung or other chest cancers. Researchers want to understand why some people respond better to treatment than others, even when their cancer stage is the same. By gathering data from routine care, they hope to i…
Sponsor: Dutch Society of Physicians for Pulmonology and Tuberculosis • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Massive cancer database aims to unlock secrets of the disease
Knowledge-focused Recruiting nowThis study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…
Sponsor: University of Nebraska • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC